Skip to Content
 

News: Breast Cancer

Study examines new breast cancer drug combination

Thursday, April 27th, 2017

A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy. The study, published in Cancer Research, was led by first author Valerie Jansen, M.D., Ph.D., instructor in Medicine. Valerie […]

Vanderbilt’s Pietenpol joins Sledge as a Chief Scientific Advisor for Susan G. Komen

Thursday, April 6th, 2017

Jennifer Pietenpol, Ph.D., Executive Vice President for Research at Vanderbilt University Medical Center (VUMC) and director of Vanderbilt-Ingram Cancer Center (VICC), has been named a Chief Scientific Advisor (CSA) for the nonprofit breast cancer organization Susan G. Komen. Jennifer Pietenpol, Ph.D. She joins George Sledge Jr., M.D., professor of Medicine at Stanford University Medical Center, […]

Breast cancer program lands new research grants

Friday, March 24th, 2017

Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients. The grants totaling more than $3 million will fund mechanistic science and clinical trials designed to test novel therapy combinations and determine why some forms of breast cancer become resistant […]

Chance to sing for the Pope motivates cancer patient

Thursday, January 26th, 2017

Cancer patient Sharon Edwards will lift her voice toward what she hopes is a better year when she sings for Pope Francis later this month. “I used to be a soprano until radiation turned me into an alto,” she said, attempting to hold back a tear with humor. She doesn’t always succeed. It’s hard not […]

Targeting the “un-targetable”

Thursday, December 1st, 2016

Triple negative breast cancers (TNBC) are so named because they lack common genetic “target” mutations that can be easily treated with specific cancer drugs. However, in a recent study published in Molecular Cancer Therapeutics, Deborah Lannigan, Ph.D., and colleagues investigated a new target involved in TNBC called RSK. They demonstrated that RSK can help cancers […]

Screening mammograms now offered at four locations

Thursday, October 13th, 2016

One in eight women will be diagnosed with breast cancer in their lifetime and those cancers are often detected through screening mammograms. A mammogram is a low-dose X-ray of the breast that enables an imaging specialist to look for changes in breast tissue that could indicate cancer. The American Cancer Society, the National Comprehensive Cancer […]

Breast imaging’s Huff dedicated to precision

Thursday, September 29th, 2016

A series of beautiful photographs of turquoise waves curling over a sandy beach sits above the desk of John Huff, M.D. An accomplished photographer whose work has been exhibited at shows in Nashville as well as regional invitational shows in Louisville, Birmingham, and the International Center for Photography in New York, Huff said most people […]

BMI genotype and breast cancer risk

Thursday, September 29th, 2016

Being overweight is associated with decreased risk of breast cancer before menopause and increased risk after menopause. In a study published recently in PLOS Medicine, Wei Zheng, Ph.D., M.D., and colleagues investigate these contrasting associations. They use data from 145,056 women, and a list of genetic variants found in genomic studies to be associated with […]

National Lymphedema Network honors VUMC research efforts

Thursday, September 22nd, 2016

Lymphedema research conducted at Vanderbilt University Medical Center (VUMC) to better understand patient risk for this chronic condition and treatment responses received recognition at an international conference. Paula Donahue, DPT, assistant professor of Physical Medicine and Rehabilitation, recently received Best Research Award in the new investigator category at the 2016 National Lymphedema Network Conference, which […]

In search of new cancer targets

Thursday, September 15th, 2016

Molecularly heterogeneous cancers such as triple-negative breast cancer are challenging to treat, because they often lack the “driver” mutations that are targeted by the newest cancer therapies. These cancers exhibit genomic instability, resulting in chromosomal rearrangements and gene fusions, and identifying these alterations is technically difficult. Timothy Shaver and Brian Lehmann, Ph.D., working with Jennifer […]

Next Page »« Previous Page